FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
|Articles|December 31, 2006
Chronic Cough-the Whole Ball of Wax
When you are not certain about theorigin of a patient’s chronic cough,check the ears for cerumen impaction.
Advertisement
When you are not certain about theorigin of a patient's chronic cough,check the ears for cerumen impaction.Although postnasal drip,asthma, and gastroesophageal refluxdisease are more common causes,cerumen impaction can activate thecough reflex through stimulation ofArnold's nerve. Removal of impactedwax may resolve the cough and eliminatethe need for radiographs orblood work.
-- Ali Ahmadizadeh, MD
Hoboken, NJ
Advertisement
Related to this article
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5